Biotech likes to do crazy things in Q4 of midterm years... now that all leverage has been wiped out by the October rollercoaster, it's time for blue sky soon IMO. 🫡📈 $ARKG $PDSB $QSI $NAUT

Biotech theme is back... 🫡📈 Really think that $PDSB is still quite early compared to $NAUT and $QSI (still like both) as it's having a brand new breakout today. Despite the green day, IMO this is way better than buying at $1.80 2 weeks ago. 👍 Phase 2 data published in JAMA Oncology showed a 36% objective response rate in CPS ≥1 patients, versus a 19% historical benchmark. Patrick Soon-Shiong from $IBRX is also now on the cap table... nice. Congrats to those who rode $NAUT and $QSI with me... think our current biotech focus is trying to get more $PDSB, as other ideas are REALLY starting to run.

BIOTECH FOUNDER WHOSE FAMILY RECEIVED APPROXIMATELY $700 MILLION FROM A COMPANY SALE IS NOW FIGHTING FOR AN ADDITIONAL $365 MILLION IN DELAWARE’S SUPREME COURT. Immunomedics founder David Goldenberg is challenging a Delaware Chancery ruling that rejected his interpretation of a revenue-sharing agreement following Gilead Sciences’ $21 billion acquisition of the company. Goldenberg’s employment agreement entitled him to 1.5% of certain company revenue. He argues that after the acquisition, Gilead became an affiliate under the agreement, entitling him to a share of revenue across Gilead’s businesses. Chancery disagreed, finding the agreement was intended to compensate Goldenberg for revenue connected to his scientific research, not unrelated businesses owned by the acquirer. Goldenberg asked Delaware’s Supreme Court on Wednesday to reverse that ruling. The dispute centers on how broadly an acquisition can expand a founder’s contractual compensation rights.